Innovation Pharmaceuticals Inc (IPIX)

[cabel]

I sent Leo a question on a drug posted here,.. just got a response,..

We are very busy here and probably I shouldn't waste my time addressing pseudoscience articles, however, I believe it is important that our shareholders understand the facts.

Critical's COTI-2 with the nanomolar potency expects that they will be efficacious and safer based on assumption that they can be used at lower doses. However, this rule ignores critical parameters affecting efficacy and toxicity such as physiochemical and absorption, distribution, metabolism and excretion properties, and off-target effects. There are examples of clinically failed compounds with nanomolar potency such as COX-2 inhibitor. The drug like compounds should have a good therapeutic window. Kevetrin has an excellent therapeutic window. It has shown good efficacy in p53 wild type as well as p53 mutant xenograft models. Kevetrin shows IC50 for most cancer cells in micro-molar range whereas IC50 for normal cells such as dermal fibroblast is in milli-molar range indicating excellent therapeutic window. There are instances where effective compounds that would have been discarded during initial stages of drug discovery simply because they did not exhibit nonomolar potency and compounds with nanomolar potency that failed during clinical testing. Clinically efficacious compound does not necessarily need to work at nanomolar rage but it should have excellent therapeutic window. Which we expect from compounds like Kevetrin. What counts are clinical results!